Dmitry Balyasny’s Rocket Pharmaceuticals RCKT Stock Holding History

Dmitry Balyasny’s Portfolio RCKT Stock Details RCKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$322K	Sell	94,264 -164,743	-64%	-$548K	﹤0.01%	2688
2026 Q1	$927K	Sell	259,007 -141,699	-35%	-$563K	﹤0.01%	2110
2025 Q4	$1.41M	Sell	400,706 -913,031	-69%	-$3.13M	﹤0.01%	2030
2025 Q3	$4.28M	Buy	1,313,737 +1,181,931	+897%	+$3.72M	0.01%	1434
2025 Q2	$323K	Sell	131,806 -221,151	-63%	-$1.12M	﹤0.01%	2456
2025 Q1	$2.35M	Buy	+352,957	New	+$3.49M	﹤0.01%	1630
2023 Q4	–	Sell	-34,205	Closed	-$701K	–	2827
2023 Q3	$701K	Buy	+34,205	New	+$622K	﹤0.01%	1657
2023 Q1	–	Sell	-542	Closed	-$10.6K	–	3065
2022 Q4	$10.6K	Sell	542 -49,228	-99%	-$907K	﹤0.01%	2551
2022 Q3	$794K	Buy	+49,770	New	+$777K	﹤0.01%	1891
2017 Q1	–	Sell	-18,025	Closed	-$440K	–	1753
2016 Q4	$440K	Buy	18,025 +5,525	+44%	+$158K	﹤0.01%	1178
2016 Q3	$474K	Buy	+12,500	New	+$393K	﹤0.01%	749

Other funds holding RCKT

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Dmitry Balyasny's RCKT Position: Q2 2026 in Review

Dmitry Balyasny reduced its Rocket Pharmaceuticals (RCKT) stake by 64% in Q2 2026, selling an estimated $548K and leaving 94,264 shares worth $322K. The position accounts for ﹤0.01% of the portfolio, ranked #2688.

Dmitry Balyasny first reported a position in RCKT in Q3 2016 and has held it in 11 quarters since. The position peaked at $4.28M in Q3 2025. 178 funds tracked by Wall St. Rank hold RCKT as of Q2 2026.

Dmitry Balyasny held 94,264 shares of Rocket Pharmaceuticals worth $322K as of Q2 2026.
Dmitry Balyasny sold 164,743 Rocket Pharmaceuticals shares in Q2 2026, an estimated $548K.
Rocket Pharmaceuticals made up ﹤0.01% of Dmitry Balyasny's portfolio in Q2 2026, its #2688 holding.
Dmitry Balyasny first reported a position in Rocket Pharmaceuticals in Q3 2016 and has held it in 11 quarters since.
Dmitry Balyasny's Rocket Pharmaceuticals position peaked at $4.28M in Q3 2025.
178 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.